# To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

> **NCT02262689** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK2256294
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02262689
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-08
- **Primary completion:** 2015-04-24
- **Final completion:** 2015-04-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262689, "To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02262689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*